Quarterly report pursuant to Section 13 or 15(d)

Accrued Liabilities and other Long-Term Liabilities (Details)

v3.19.3
Accrued Liabilities and other Long-Term Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Dec. 31, 2018
Accrued expenses:    
Professional fees $ 1,577 $ 1,434
Salaries, bonuses and related benefits 5,863 5,843
Research and development 3,285 3,805
Research and development - manufacturing 919 826
Research and development - clinical supplies 159 160
Research and development - license maintenance fees 689 519
Research and development - milestones 500 200
Dr. Falk Pharma milestone   300
Accrued royalties payable 1,833 1,108
Accrued coupon expense 1,994 838
Other 2,586 1,327
Total accrued expenses 19,405 16,360
Other long-term liabilities:    
Deferred rent and long-term lease abandonment charge 2,183 5,211
Long-term note payable 68,542 60,425
Total other long-term liabilities 7,025 5,211
Ximino [Member]    
Other long-term liabilities:    
Long-term note payable $ 4,842 $ 0